



Index Level

Index	Close	S1	S2	R1	R2
NIFTY	17657	17852	17536	17704	17750
BANKNIFTY	42146	41941	41737	42371	42595

Nifty Snapshot

Description	21-April	20-April
Nifty Spot	17624	17624
Nifty April	17657	17655
Nifty May	17950	17900
MACD (12,26,9)	82.90	85.88
RSI (14)	56.04	56.04
50 Day SMA	17,509	17,509
100 Day SMA	17,854	17,854
200 Day SMA	17,596	17,596

Nifty Option OI Concentration
Figure in Lakhs

Nifty Option OI Change
Figure in Lakhs

Nifty Outlook
SGX 17,660 (20.5)

Today the markets are likely to open on a flat note. Singapore Nifty and other Asian markets are trading in sideways zone. The coming session is likely to witness a range of 17600 on declines and 17800 on advances.

Stock is in ban period

None

Sentiment Indicator

	20-April	19-April	18-April	17-April	14-April
NIFTY Discount/Premium	33	27	51.85	76	82.9
COST OF CARRY%	0.18	0.15	0.29	0.43	0.47
PCR(OI)	0.81	0.63	1.24	1.10	1.28
PCR(VOL)	0.93	0.95	0.94	0.98	0.89
A/D RATIO (Nifty 50)	1.01	0.58	2.84	2.33	6.14
A/D RATIO (All Stocks)	0.60	0.81	3.00	4.13	2.70
ATM IV, CE	8.27	11.03	11.79	9.4	8.15
VIX	11.6	12.15	12.27	12.60	12.93
ATM IV, PE	9.12	11.67	13.39	11.46	12.19


**All Future Stock*
Nifty v/s OI

Date	Nifty	% Change	Open Interest	% Change
21-April	17657.3	0.01%	9439350	1.95%
20-April	17655	0.03%	9673150	4.35%
19-April	17645	-0.38%	9477700	3.79%
18-April	17712.35	-0.27%	9131350	-2.18%
17-April	17760.1	-0.67%	9334400	-1.31%
13-April	17879.65	0.12%	9458050	+1.74%
12-April	17858.25	0.13%	9296000	-0.34%


Fund Flow (FII/DII)

Description	Net investment (in cr)
FII CASH	-2116.76
DII CASH	+1632.66
FII IDX FUTURE	+104.53
FII IDX OPTION	-3895.86
FII STK FUT	+467.86
FII STK OPTION	+48.46

FII's activity in Nifty future



Nifty discount / premium



Amt in Crores

Top 10 long build up stocks

Scrip	LTP	%Chg	OI	%ChgOI
PERSISTENT 27APR2023	4297.55	0.25	1122975	8.29
NAVINFLUOR 27APR2023	4718.2	0.95	461400	5.74
MFSL 27APR2023	623.8	-2.99	4756050	4.01
PVR 27APR2023	1501.15	-0.88	2194544	2.96
ITC 27APR2023	407.25	1.71	61814400	2.11
LTTS 27APR2023	3335.1	0.03	1434200	1.73
SHRIRAMFIN 27APR2023	1359.15	1.18	4301400	1.52
BANDHANBNK 27APR2023	221.2	1.21	50223600	1.46
RBLBANK 27APR2023	148	-1.4	34750000	1.03
CUB 27APR2023	130.45	-2.39	23600000	1.01

Top 10 short build up stocks

Scrip	LTP	%Chg	OI	%ChgOI
HCLTECH 27APR2023	1051.65	1.39	9412200	-19.55
PIIND 27APR2023	3194.1	1.07	1803500	-18.7
SYNGENE 27APR2023	617	-0.03	1988000	-16.12
NMDC 27APR2023	109.8	-2.14	40869000	-14.51
ALKEM 27APR2023	3412.5	1.29	560600	-13.3
APOLLOHOSP 27APR2023	4366.4	0.31	1204125	-12.43
COROMANDEL 27APR2023	942.15	1.15	1118600	-12.34
AUOPHARMA 27APR2023	587.85	1.08	10259000	-11.7
CANBK 27APR2023	295.25	-0.56	34435800	-11.68
BATAINDIA 27APR2023	1481.55	1.25	2354825	-11.4

Indices to out perform

Scrip	Closing	% change
Media	1706.65	+1.33
FMCG	46669.70	+0.89
I.T.	26822.10	+0.69
PHARMA	12545.75	+0.48

Indices to under perform

Scrip	Closing	%change
Realty	423.50	-2.13
Metal	5677.90	-1.37
Auto	12898.75	-1.03
PSU BANK	3883.00	-0.84

Stocks to out perform

Scrip	Closing	% change
IDEA	6.45	+6.61
NACTOPHARMA	555.35	+2.07
PAGEIND	40054.70	+2.03
ITC	408.25	+1.99

Stocks to under perform

Scrip	Closing	%change
Oberoi Realty	873.35	-4.40%
Gland Pharma	1311.20	-3.90%
Dalmia Bharat	1922	-3.36%
HDFC Life Insurance	513.30	-3.20%

Top 10 High PCR Ratio Stocks

Scrip	Put	Call	P/C Ratio
TATACOMM	3117500	2073500	1.5
BAJAJ-AUTO	2816500	2315250	1.22
VEDL	24500000	23022000	1.06
AUBANK	9645000	9280000	1.04
BANDHANBNK	15179400	14797800	1.03
NESTLEIND	178640	177280	1.01
GLENMARK	3752600	3804800	0.99
AUROPHARMA	6663000	6882000	0.97
BIOCON	10235000	10708800	0.96
GODREJPROP	2259725	2341750	0.96

Top 10 Low PCR Ratio Stocks

Description	Put	Call	P/C Ratio
ABBOTINDIA	8040	71480	0.11
RAMCOCEM	232900	1523200	0.15
SHREECEM	33050	193050	0.17
HONAUT	1935	8775	0.22
MFSL	399750	1807000	0.22
ALKEM	47600	207600	0.23
SBILIFE	978750	4038000	0.24
MRF	5480	21570	0.25
TORNTPHARM	110000	434500	0.25
OFSS	44800	172600	0.26

Top 30 High Delivery Stocks

Company	Deliverable Qty	Traded Qty	% Dly Qty To Trd Qty
SUNDARMFIN	46803	48757	95.99
FLUOROCHEM	319916	342377	93.44
KEC	779808	841429	92.68
KAJARIACER	137396	157332	87.33
AJANTPHARM	66950	78546	85.24
KFINTECH	249226	292698	85.15
MSUMI	3262020	3887252	83.92
NAM-INDIA	321514	383879	83.75
ASTERDM	384733	472717	81.39
CCL	147311	183443	80.3
LAXMIMACH	9089	11443	79.43
CERA	11898	15200	78.28
BCG	19773380	25729451	76.85
RAINBOW	133790	174264	76.77
VBL	1384917	1807712	76.61
NYKAA	13623903	17843321	76.35
BHARTIARTL	3405157	4524208	75.27
SANOFI	17808	23952	74.35
CIPLA	2568331	3481218	73.78
MEDANTA	160492	218984	73.29
HINDUNILVR	883812	1206288	73.27
JSL	485985	665410	73.04
GALAXYSURF	26363	36179	72.87
ATUL	20577	28429	72.38
MANYAVAR	112882	156178	72.28
TMB	35862	49655	72.22
VMART	13418	18658	71.92
INFY	6169479	8691352	70.98
TORNTPHARM	309880	441046	70.26
PRESTIGE	585893	834820	70.18

52-week high stocks

Company	Price (Rs)	Day High
Cyient	1,159.65	1,193.70
ITC	408.25	409
Alkem Laboratories	3,409	3,462.35
Godrej Consumer Prod	987.15	990.75
Bajaj Auto	4,308.30	4,337
Anupam Rasayan India	1,059.80	1,076.80
Axita Cotton	73.75	74.05
Global Surfaces	215.2	216.3
Zydus Lifesciences	518.75	520.65
Apar Inds	2,837.75	2,885

52-week low stocks

Company	Price	Day's Low
FSN E-Commerce	120.6	120.15
Aavas Financiers	1,579	1,562.10
India Glycols	539.35	537.1
Indoco Remedies	310	307.3
GRM Overseas	169.2	164.75
EKI Energy Services	436.25	436.25
BEML Land Assets	246.1	246.1
Tashi India	116.5	116
Sancode Technologies	57.36	52.14
Punjab Chem. & Corp	808.7	806

VP – Head Research - Dr. Ravi Singh
Mob: +919810313561
Email ID: ravi.singh@shareindia.com

Disclosure:

We, research team at Share India Securities Ltd. (SISL), authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. SISL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

We state that Research Analyst or his/her relative or SISL may have any financial interest in the subject company. Also Research Analyst or his relative or SISL or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report.

Further, Research Analyst or his relative or SISL or its associate a) does not have any material conflict of interest at the time of publication of the research report; b) has not managed or co-managed public offering of securities for the subject company in the past twelve months; c) has not received any compensation for investment banking or merchant banking or brokerage services or for any other product/s or service/s or for any other reason whatsoever from the subject company in the past twelve months; d) has not received any compensation or other benefits from the subject company or third party in connection with the research report; e) has not served as an officer, director or employee of the subject company; and f) has not been engaged in market making activity for the subject company.

SISL is a SEBI Registered Research Analyst having registration no. INH100005011.

Disclaimer:

This report has been prepared by SISL and is meant for sole use by the recipient and not for circulation. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable.

Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. This document is for information purposes only. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete and this document is not, and should not be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SISL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of SISL.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk.

It should not be considered to be taken as an offer to sell or a solicitation to buy any security. SISL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

SISL and its affiliated company(s), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(s) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(s) discussed herein or act as an advisor or lender/borrower to such company(s) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

SISL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SISL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

SISL is a Member of National Stock Exchange of India Limited (NSE), BSE Ltd (Bombay Stock Exchange), Multi Commodity Exchange of India Limited (MCX), National Commodity and Derivatives Exchange Limited (NCDEX), Indian Commodity Exchange Limited (ICEX) and has Depository Participant affiliation with Central Depositories Services (India) Limited (CDSL). It is a SEBI registered Portfolio Manager and SEBI registered Research Analyst [SEBI Reg. No. INB/F/E 231079832, INB/F/E 011079838, IN-DP-32-2015, AMFI Reg. No. ARN: 78041, SEBI Research Analyst Reg. No.: INH100005011, CIN - L67120G1994PLC115132]